Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Early life body size, growth and risks of systemic lupus erythematosus - A large Danish observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

Objective: . To assess the role of LN as a risk factor for myocardial infarction (MI), stroke and cardiovascular mortality (CVM) in patients with SLE.

Methods: . The study was conducted using individual-level data from multiple nationwide registers. We identified a cohort of patients diagnosed with SLE and further determined if they had a diagnosis of LN during 1995-2011. Each SLE patient was matched with five population controls. Hazard ratios (HRs) were calculated to measure the risk of MI, stroke and CVM in SLE patients relative to population controls and in SLE patients with relative to without LN.

Results: . We identified 1644 SLE patients with incident SLE; 233 of these patients had a diagnosis of incident LN during follow-up. The number of events in the SLE cohort was: 42 (MI), 74 (stroke) and 56 (CVM). For MI, the HR was 2.2 (95% CI: 1.4, 3.4) in SLE without LN and 18.3 (95% CI: 5.1, 65) in SLE with LN. The HR for LN was 8.5 (95% CI: 2.2, 33; P = 0.002). For stroke, HRs were 2.1 (95% CI: 1.5, 2.9) and 4.1 (95% CI: 1.9, 8.7) in SLE without and with LN, respectively, and we found no significant association with LN (P = 0.115). For CVM, the respective HRs were 1.6 (95% CI: 1.1, 2.4) and 7.8 (95% CI: 3.0, 20). The corresponding HR for LN was 4.9 (95% CI: 1.8, 13.7; P = 0.002).

Conclusion: . The risk of MI and CVM, but not of stroke, is significantly higher in SLE patients with LN than SLE patients without LN.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume56
Issue number5
Pages (from-to)709-715
Number of pages7
ISSN1462-0324
DOIs
Publication statusPublished - 1 May 2017

    Research areas

  • Adult, Cardiovascular Diseases, Case-Control Studies, Denmark, Female, Humans, Lupus Erythematosus, Systemic, Lupus Nephritis, Male, Middle Aged, Myocardial Infarction, Risk Factors, Stroke, Journal Article

ID: 52381028